Introduction
Phenylketonuria (PKU), one of the best investigated inherited metabolic diseases in man is caused by the deficiency of phenylalanine hydroxylase (PAH). This enzyme is expressed mainly in mammalian liver tissues including man. It has been purified and characterized from rat kidney (1).
We have described the purification of human liver PAH the generation of polyclonal antibodies and expression of an immunoreactive protein in different human tissues and cells (2) . In this report we will prove the expression of PAH in rat and human kidney by biochemical and immunological methods. Further, we will report preliminary results of expression studies in leucocytes of PKU patients and heterozygote individuals.
Methods
The PAH from rat liver and kidney was purified according to the method of Shiman (3). Polyclonal antibodies against rat liver PAH were raised in rabbits as described for human liver PAH (2). Human kidney PAH was partially purified by ammonium sulphate precipitation followed by hydrophobic-interaction and ion-exchange chromatography as described for human liver PAH (2) . Proteolytic fragments were produced by the incubation of purified PAH-probes with a-chymotrypsin (SIGMA) or SV8 protease from Staphylococcus aureus (SIGMA) according to Cleveland (4) . The fragments were separated by SDS-gel electrophoresis, blotted onto nitrocellulose and immunodetected by the specific antibody preparation.
Leucocyte extracts from patients and family members were prepared as described and investigated by Western blotting with anti hPAH-IX/27-IgG (2).
Results and Discussion
PAH was purified from rat liver (240-fold, 20% recovery), rat kidney (200-fold, 13%), human liver (105-fold, 62%) and human kidney (56-fold, 34%). In both species the molecular weight and the isoelectric point of the liver and kidney enzyme were almost identical. Two isoelectric forms of phenylalanine hydroxylase could be found in rat and probably three forms in human tissues. No differences could be shown in the rate of inhibition of PAH-activity by p-chlor-phenylalanine, 6-F-tryptophan and 3-I-tyrosine in liver and kidney preparations (results not shown). The apparent K m -values for phenylalanine, obtained with purified enzyme, were 0.396 χ 10~3 mol/1 and 0.932 χ 10~3 mol/1 for rat liver and kidney and 0.358 χ 10~3 mol/1 and 0.749 χ 10" 3 mol/1 for human liver and kidney, respectively.
The results of the biochemical investigations of purified PAH from liver and kidney in rat and human suggest strongly the expression of PAH also in human kidney. To show that this is really the same enzyme we have investigated the peptide structure after proteolytic digestion with a-chymotrypsin and SV8 protease (Fig. 1) . In both species there are no differences in the pattern of peptides obtained in liver and kidney preparation, which is an further evidence for the expression of PAH in kidney. Although we have used ft· Figure 1 . Peptide mapping-analysis of purified PAH from rat (A) and from human (B) liver (L) and kidney (N).
partially purified human kidney PAH for these experiments, no other peptides were detected by the antibodies, suggesting their high specifity.
Using these polyclonal antibodies, raised against human liver PAH, we could shown the presence of an immunoreactive protein which has the same molecular weight as human liver PAH in kidney, heart, pancreas, spleen, brain, lung, leucocytes, platelets, cultivated skin fibroblasts and chorionic cells (2) . To check whether this protein will be expressed in PKU patients, we have investigated leucocyte extracts from different patients and their parents by western blotting after SDS-gel electrophoresis (Fig. 2) . We found non or a weak immunoreaction in leucocytes of nine PKUpatients. The immunoreactive protein with the same molecular weight as PAH was not detectable in leucocytes of two patients (Fig. 2 able PAH (5). On the other hand, the same amount of immunoreactive protein as in normal leucocytes will be expressed in leucocytes of patients with the haplotypes 3/4 and 6/1. The results obtained in these preliminary investigations suggest the expression of PAH in blood cells. Using specific antibodies with high affinity the detection of even low amounts of PAH-protein should be possible and helpful in the characterization of mutant PAH. But, these results should be assessed critically and confirmed by other investigators.
